Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
Gil da Costa RM, Levesque C, Bianchi-Frias D, Chatterjee P, Lam HM, Santos C, Coleman IM, Ferreirinha P, Vilanova M, Pinto da Cunha N, Carvalho H, Moreira-Pais A, Faustino-Rocha A, Neto T, Batista da Costa J, Wright JL, Ferreira R, Oliveira PA, Mendes J, Bastos MMSM, Colaço B, Lopes C, Black PC, Sweeney CJ, Nelson PS. Gil da Costa RM, et al. Among authors: lam hm. Mol Oncol. 2023 Dec;17(12):2709-2727. doi: 10.1002/1878-0261.13504. Epub 2023 Sep 20. Mol Oncol. 2023. PMID: 37533407 Free PMC article.
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
Makrakis D, Wright JL, Roudier MP, Garcia J, Vakar-Lopez F, Porter MP, Wang Y, Dash A, Lin D, Schade G, Winters B, Zhang X, Nelson P, Mostaghel E, Cheng HH, Schweizer M, Holt SK, Gore JL, Yu EY, Lam HM, Montgomery B. Makrakis D, et al. Among authors: lam hm. Clin Genitourin Cancer. 2023 Apr;21(2):265-272. doi: 10.1016/j.clgc.2022.12.003. Epub 2022 Dec 23. Clin Genitourin Cancer. 2023. PMID: 36710146 Clinical Trial.
Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.
Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seiler R, Black PC, Boormans JL, Dall Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BWG, van der Heijden MS, Hsieh AC, Wright JL, Lam HM. Winters BR, et al. Among authors: lam hm. Urol Oncol. 2018 Jul;36(7):342.e7-342.e14. doi: 10.1016/j.urolonc.2018.03.016. Epub 2018 Apr 12. Urol Oncol. 2018. PMID: 29657089 Free article.
Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC. Seiler R, et al. Among authors: lam hm. Clin Cancer Res. 2019 Aug 15;25(16):5082-5093. doi: 10.1158/1078-0432.CCR-18-1106. Epub 2018 Sep 17. Clin Cancer Res. 2019. PMID: 30224344 Free article.
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam HM, Roudier M, Lange PH, Nelson PS, Corey E. Nguyen HM, et al. Among authors: lam hm. Prostate. 2017 May;77(6):654-671. doi: 10.1002/pros.23313. Epub 2017 Feb 3. Prostate. 2017. PMID: 28156002 Free PMC article.
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.
Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E. Lam HM, et al. Eur Urol. 2020 Feb;77(2):144-155. doi: 10.1016/j.eururo.2019.05.042. Epub 2019 Jun 19. Eur Urol. 2020. PMID: 31227306 Free PMC article.
Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.
Ruppender N, Larson S, Lakely B, Kollath L, Brown L, Coleman I, Coleman R, Nguyen H, Nelson PS, Corey E, Snyder LA, Vessella RL, Morrissey C, Lam HM. Ruppender N, et al. Among authors: lam hm. PLoS One. 2015 Jun 19;10(6):e0130565. doi: 10.1371/journal.pone.0130565. eCollection 2015. PLoS One. 2015. PMID: 26090669 Free PMC article.
SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, Lam HM, Dumpit R, Corey E, Chéry L, Lakely B, Higano CS, Montgomery B, Roudier M, Lange PH, Nelson PS, Vessella RL, Morrissey C. Zhang X, et al. Among authors: lam hm. Clin Cancer Res. 2015 Oct 15;21(20):4698-708. doi: 10.1158/1078-0432.CCR-15-0157. Epub 2015 Jun 12. Clin Cancer Res. 2015. PMID: 26071481 Free PMC article.
255 results